Is innovation becoming a lost art in the pharmaceutical industry? A new survey of 282 pharmaceutical executives, done at the behest of clinical research organization Quintiles, found that 54 percent consider innovation to be a leading priority and 49 percent rank their overall innovation strategy as, at best, moderately effective, says Pharmalot's Ed Silverman. Sixteen percent of the executives agreed that improving innovation was the most important priority for success, and 38 percent considered it among the top priorities. Seven percent said change wasn't even needed. Almost half of those surveyed said cost was a major impediment to improving innovation strategies, Silverman says, while others cited lack of time and overly restrictive regulatory standards. "In biopharma, academic research was cited as the second most common source of ideas over the coming three years — 38 percent, to be exact," Silverman says. "Internal R&D remains the leading source of innovation as a whole, cited by 60 percent, but over the next three years, just 46 percent of the execs say internal R&D will be a good source." So how does a company go about creating an environment of innovation? Rewards are a good idea, Silverman says. The survey respondents who considered themselves "innovation leaders" said they offer financial rewards for innovative ideas.
Jul 13, 2011